Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Payables (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Payables for 15 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 9.24% to $14.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.3 million, a 9.24% decrease, with the full-year FY2025 number at $10.6 million, down 16.59% from a year prior.
  • Payables was $14.3 million for Q4 2025 at Aytu Biopharma, up from $12.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $25.1 million in Q1 2023 to a low of $9.4 million in Q3 2021.
  • A 5-year average of $14.6 million and a median of $14.7 million in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: surged 1281.89% in 2021, then tumbled 51.92% in 2024.
  • Aytu Biopharma's Payables stood at $15.6 million in 2021, then increased by 15.41% to $18.0 million in 2022, then plummeted by 36.15% to $11.5 million in 2023, then surged by 36.63% to $15.7 million in 2024, then dropped by 9.24% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Payables are $14.3 million (Q4 2025), $12.3 million (Q3 2025), and $10.6 million (Q2 2025).